Endocrine Abstracts

JOINT2480

Background: Obese individuals can exhibit normal or high IGF-1 levels. The relationship between IGF-1 levels and body mass index (BMI) is not clear. Inflammatory changes and various metabolic features in obese patients may explain this difference. The clinical features of obese patients with low IGF-1 levels are important. It was suggested that obese people with low IGF-1 levels may have more adiposity, inflammation, and metabolic problems like dyslipidemia and hyperuricemia. Obese individuals are known to exhibit a chronic low-level inflammation state. Systemic immune-inflammatory markers are new markers that indicate chronic subclinical inflammation in various diseases. The neutrophil/lymphocyte ratio (NLR), the platelet/lymphocyte ratio (PLR), the lymphocyte/monocyte ratio (LMR), the systemic immune-inflammation index (SII), the systemic inflammatory response index (SIRI), and the systemic inflammation aggregate index (SIAI) are some of these indicators. Obese individuals have demonstrated high levels of SII, NLR, and PLR. This study aimed to evaluate the relationship between IGF-1 levels and systemic immune-inflammatory markers with metabolic comorbidities in patients with obesity.

Methods: We examined 210 obese subjects with a BMI ≥ 35 kg/m². For each age and gender, a standard IGF-1 standard deviation score (SDS) was used to figure out what the IGF-1 levels meant (low IGF-1 group: ≤ −2.0 SDS and standard IGF-1 group: −2.0 and +2.0 SDS). We recorded demographic characteristics, BMI, blood pressure, hypertension, diabetes, hyperuricemia status, NLR, PLR, LMR, SII, SIRI, and SIAI values.

Results: In this study, 7.62% of the subjects had low IGF-1 levels. NLR and SII were significantly higher in the standard IGF-1 group compared to low IGF group. Low IGF-1 levels do not correlate with systemic inflammatory markers. SII was found to be correlated with systolic blood pressure, ALT, and insulin levels. SIAI was correlated with systolic blood pressure. Rate of hypertension was higher in the low IGF 1 group. Low IGF-1 levels were not associated with diabetes and hyperuricemia.

Conclusion: This study is the first to demonstrate the relationship between IGF-1 and immune-inflammatory markers in obese patients. These results suggest that low IGF-1 levels may not be associated with increased inflammation and metabolic disorders in obese patients. Some of these markers were low in the low IGF-1 group, which may explain why metabolic complications were less common in this group.